COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,884 Articles (22,568 medRxiv, 8,316 bioRxiv)

Most recent first Previous |  Page 2636: Articles 26351-26360  | Next

Potential impact of Covid-19 response measures on invasive pneumococcal disease in England and Wales
Choi, Y. H., Miller, E.
10.1101/2020.06.01.20119057 — Posted: 2020-06-02
Quantitative assessment of the risk of airborne transmission of SARS-CoV-2 infection: prospective and retrospective applications
Buonanno, G., Morawska, L., Stabile, L.
10.1101/2020.06.01.20118984 — Posted: 2020-06-02 Discussion: Onsite
CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients
Dominguez Horta, M. d. C.
10.1101/2020.05.27.20110601 — Posted: 2020-06-02
The prevalence of antibodies to SARS-CoV-2 in asymptomatic healthcare workers with intensive exposure to COVID-19
Xiong, S., Guo, C., Dittmer, U., Zheng, X., Wang, B.
10.1101/2020.05.28.20110767 — Posted: 2020-06-02
Antibody profiling of COVID-19 patients in an urban low-incidence region in Northern Germany
Solbach, W., Schiffner, J., Backhaus, I., Burger, D., Staiger, R., Tiemer, B., Bobrowski, A., Hutchings, T., Mischnik, A.
10.1101/2020.05.30.20111393 — Posted: 2020-06-02
A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients.
Tan, C. W., Ho, L. P., Kalimuddin, S., Cherng, B. P. Z., Teh, Y. E., Thien, S. Y., Wong, H. M., Tern, P. J. W., Chay, J. W. M., Low, J. G. H., Ng, H. J.
10.1101/2020.06.01.20112334 — Posted: 2020-06-02 Discussion: Onsite
COVID-19: Why SOLIDARITY and DisCoVeRy trials may fail to bring informative and timely results
TOUMI, M., LIANG, S., DABBOUS, M., WANG, Y., QIU, T., HAN, R.
10.1101/2020.06.01.20118927 — Posted: 2020-06-02
Mathematical Modeling and Analysis of COVID-19 pandemic in Nigeria
Iboi, E. A., Sharomi, O. O., Ngonghala, C. N., Gumel, A. B.
10.1101/2020.05.22.20110387 — Posted: 2020-06-02
Serological surveys in Reunion Island of the first hospitalized patients revealed that long-lived immunoglobulin G antibodies specific against SARS-CoV2 virus are rapidly vanishing in severe cases
Dobi, A., Frumence, E., LALARIZO RAKOTO, M., Lebeau, G., Vagner, D., SANDENON SETEYEN, A.-L., Giry, C., Septembre-Malaterre, A., Jaffar-Bandjee, M.-C., Raffray, L., Gasque, P.
10.1101/2020.05.25.20112623 — Posted: 2020-06-02
SCALE19: A scalable and cost-efficient method for testing Covid-19 based on hierarchical group testing
Kim, J. S., Kim, J. S., Kim, H.
10.1101/2020.06.01.20119172 — Posted: 2020-06-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).